SCHEMBL2890443

SCHEMBL2890443

CC(=O)Nc1ccc(Cl)cc1CO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.58
HSD17B10 Q99714 1/20 0.58
HDAC1 Q13547 1/20 0.44
USP2 O75604 1/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 3/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
NHERF1 O14745 2/20 0.43
EPHX1 P07099 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
PARP14 Q460N5 1/20 0.42
PTK2 Q05397 1/20 0.41
DYRK1A Q13627 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9119625 0.88 KDM4E (0.60) KDM4EHSD17B10HDAC1USP2HPGD
SCHEMBL9373094 0.86 KDM4E (0.54) KDM4EHSD17B10MAPTLMNAPOLB
SCHEMBL23434997 0.82 HSD17B10 (0.54) KDM4EHSD17B10HDAC1USP2HPGD
SCHEMBL1646158 0.81 KDM4E (0.56) KDM4EHSD17B10HDAC1USP2HPGD
SCHEMBL5107971 0.81 MTNR1A (0.56) KDM4EHSD17B10HPGDMAPTLMNA
SCHEMBL2892719 0.81 KMT2A (0.47) HSD17B10HPGDMAPTPOLBNPC1
SCHEMBL14801910 0.80 POLB (0.47) KDM4EUSP2HPGDMAPTLMNA
SCHEMBL7934018 0.80 POLB (0.47) KDM4EUSP2HPGDMAPTPOLB
SCHEMBL3057713 0.80 CYP1A2 (0.56) HSD17B10USP2HPGDMAPTRAB9A
SCHEMBL3782005 0.80 KDM4E (0.68) KDM4EHSD17B10HDAC1USP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8558028-B2 Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) 2013-10-15 US disclosed
US-8558028-B2 Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) 2013-10-15 US disclosed
US-8558028-B2 Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) 2013-10-15 US disclosed
CN-101918352-A Inhibitors of 17 beta-hydroxysteroid dehydrogenase STERIX LTD 2010-12-15 CN disclosed
US-20100286204-A1 COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2010-11-11 US disclosed
US-20100286204-A1 COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2010-11-11 US disclosed
US-20100286204-A1 COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2010-11-11 US disclosed
WO-2009066072-A2 COMPOUND STERIX LIMITED (GB) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286204-A1 COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE HSD17B13, HSD17B3, HSD3B2 KDM4E 1851/4885HSD17B10 12/4885HDAC1 1480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.